Julia Babensee
(she/her)
Biography
- Bulondo, F., Babensee, J.E., Optimization of Interleukin-10 Incorporation for Dendritic cells Embedded in Poly(ethylene glycol) Hydrogels, J. Biomed. Mater. Res., 1-20, (2024).
- Beskid, N.M., Kolewole, E., Coronel, M.M., Nguyen, B., Evavold, B., Garcia, A.J., Babensee, J.E., IL-10-Functionalized Hydrogels Support Immunosuppressive Dendritic Cell Phenotype and Function, ACS Biomaterials Science and Engineering, 8: 4341–4353 (2022).
- Srinivasan, S., Babensee, J.E., Dendritic Cells in the Presence of PLGA Support a Proliferative Antigen-Specific T-Cell Response, J Biomed Mater Res, 109: 2269–2279 (2021).
- Thomas, A.M., Beskid, N.M., Blanchfield, J.L., Rosado, A.M., García, A.J. Evavold, B.D., Babensee, J.E., Dendritic Cell-Delivering in situ Hydrogel for Attenuation of a Multiple Sclerosis Model, J Biomed Mat Res, 109: 1247–1255 (2021).
- Srinivasan, S., Babensee, J.E., Temporally Controlled Delivery of Multiple Immunomodulators from a Scaffold Niche to Induce Tolerogenic Functionality of Human Dendritic Cells, ACS Biomaterials Science and Engineering, 6: 4062-4076 (2020).
Education
- • 1986-1990, B.A.Sc., Chemical Engineering and Applied Chemistry University of Toronto
- • 1990-1996, Ph.D, Chemical Engineering and Applied Chemistry, University of Toronto
- • 1996-1999, Postdoctoral Fellow Department of Bioengineering, Rice University Section of Leukocyte Biology, Baylor College of Medicine
Academic Appointments
Research Interests
Dr. Babensee’s research program is in the area of immunoengineering using biomaterial-based strategies to direct immune responses for applications in regenerative medicine, autoimmunity, transplantation and vaccines. As such, her research is directed at understanding biomaterial-based effects on the phenotype of key regulators of immune responses, the professional antigen presenting cells, dendritic cells (DCs) and developing biomaterial-based strategies for directed DC-dependent immunomodulation for control of immune outcomes. She uses an in situ gelling hydrogel material to deliver DCs to disease relevant locations to alleviate the symptoms of autoimmunity in mice. Clinical translation of the approach is being investigated.